- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3003;
Copy number was highest in the epidermis for IFN-ac. Spatial transcriptomics also illuminates differences in inflammatory versus metabolic programs that are activated in immune (CD45) versus epidermal (cytokeratin positive) and dermal locations.
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing (Room 32A-B; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1793;
As oxidized DNA is resistant to degradation in the cytosol where it can serve as a potent trigger of cGAS-STING, VISTA promotion of DNA repair may indirectly suppress STING signals. Antibody-mediated activation of VISTA in keratinocytes demonstrates its potential as a target to suppress IFN-I production in the context of photosensitivity and lupus.
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Journal: Blood Genomics Identifies Three Subtypes of Systemic Lupus Erythematosus: "IFN-High," "NE-High," and "Mixed". (Pubmed Central) - Apr 1, 2022
Our research results indicated that identifying the molecular mechanism associated with different SLE subtypes would benefit the molecular diagnosis and stratified therapy. Moreover, repositioning of IFN-K based on subtypes also revealed an improved therapeutic effect, providing a new direction for disease treatment and drug development.
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Human papilloma virus infection as an antigenic stimulus in psoriasis () - Jan 15, 2022 - Abstract #PsoriasisG2C2021PsoriasisG2C_25;
IFN-k, a type III IFN, is important in the innate antiviral response and was also increased in psori-asis skin. Our findings support the hypothesis that HPV may act as an antigenic stimulus in psoriasis.
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Preclinical, Journal: Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse Model. (Pubmed Central) - Dec 25, 2021
Hence, we assessed the immunogenicity, efficacy, and tolerance of IFN-Kinoid (IFN-K), an anti-IFNα vaccination strategy, in a well-known mouse model of systemic autoimmunity with SjS-like features: MRL/MpJ-Faslpr/lpr (MRL/lpr) mice...No adverse effects were observed. We herein report on the strong efficacy of an innovative anti-IFNα vaccination strategy in a mouse model of SjS, paving the way for further clinical development (a phase IIb trial has just been completed in systemic lupus erythematosus with promising results).
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Trial completion date, Trial termination: Phase IIb Study of IFN-K in Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 9, 2020
P2b, N=185, Terminated,
We herein report on the strong efficacy of an innovative anti-IFNα vaccination strategy in a mouse model of SjS, paving the way for further clinical development (a phase IIb trial has just been completed in systemic lupus erythematosus with promising results). Trial completion date: Jun 2023 --> Feb 2020 | Active, not recruiting --> Terminated; Reorganization proceedings of the sponsor
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Study of IFN-K in Dermatomyositis (clinicaltrials.gov) - Jan 3, 2020
P2a, N=0, Withdrawn,
Trial completion date: Jun 2023 --> Feb 2020 | Active, not recruiting --> Terminated; Reorganization proceedings of the sponsor N=30 --> 0 | Trial completion date: May 2024 --> Dec 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Dec 2019
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Enrollment closed: Study of IFN-K in Dermatomyositis (clinicaltrials.gov) - Sep 23, 2019
P2a, N=30, Active, not recruiting,
N=30 --> 0 | Trial completion date: May 2024 --> Dec 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Dec 2019 Recruiting --> Active, not recruiting
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Trial initiation date, Trial primary completion date: Study of IFN-K in Dermatomyositis (clinicaltrials.gov) - Mar 22, 2019
P2a, N=30, Recruiting,
Recruiting --> Active, not recruiting Initiation date: Nov 2016 --> May 2017 | Trial primary completion date: Dec 2018 --> Dec 2020
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Trial completion date, Trial primary completion date: Phase IIb Study of IFN-K in Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 21, 2019
P2b, N=178, Active, not recruiting,
Initiation date: Nov 2016 --> May 2017 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Dec 2018 --> Jun 2023 | Trial primary completion date: Jul 2018 --> Mar 2018
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Enrollment closed: Phase IIb Study of IFN-K in Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 27, 2017
P2b, N=178, Active, not recruiting,
Trial completion date: Dec 2018 --> Jun 2023 | Trial primary completion date: Jul 2018 --> Mar 2018 Recruiting --> Active, not recruiting
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Trial primary completion date: Phase IIb Study of IFN-K in Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 28, 2017
P2b, N=178, Recruiting,
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Jul 2018
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
Trial completion: Safety of IFNa Kinoid in Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 27, 2017
P1/2, N=28, Completed,
Trial primary completion date: Jun 2017 --> Jul 2018 Active, not recruiting --> Completed
- |||||||||| Antiferon (interferon alpha kinoid) / Neovacs
New P2a trial, IO biomarker: Study of IFN-K in Dermatomyositis (clinicaltrials.gov) - Dec 2, 2016
P2a, N=30, Recruiting,
|
